top of page
Browse by category
Search
Corbus’ from Oral CB1 inverse agonist CRB-913 demonstrates favourable safety profile and emerging evidence of weight loss
Corbus Pharmaceuticals has completed the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study (CANYON-1), with completion expected in the summer of 2026. CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (CB1). This is a recognized mechanism of action for weight loss, but the first generation of experimental drugs in this cla
Browse by tag
bottom of page